Observational Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Oct 15, 2024; 16(10): 4157-4165
Published online Oct 15, 2024. doi: 10.4251/wjgo.v16.i10.4157
Small particle drug-eluting beads-transarterial chemoembolization combined with targeted therapy in the clinical treatment of unresectable liver cancer
Jing-Song Qi, Peng Zhao, Xiao-Bo Zhao, Yong-Li Zhao, Ying-Chang Guo
Jing-Song Qi, Peng Zhao, Xiao-Bo Zhao, Yong-Li Zhao, Ying-Chang Guo, Department of Interventional, The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, Henan Province, China
Author contributions: Qi JS conceptualized the study and supervised the project; Qi JS and Zhao P collected data, preformed the research, wrote the manuscript and prepared the original draft; Zhao XB, Zhao YL and Guo YC did the validation, investigation, and analysis of the data; All authors have reviewed, edited, read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Institutional Review Board of The First Affiliated Hospital of Xinxiang Medical University, No. 2019-XXLY-001.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data. So, the Institutional Review Board has waived the informed consent from patients.
Conflict-of-interest statement: The authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Jing-Song Qi, MMed, Associate Chief Physician, Department of Interventional, The First Affiliated Hospital of Xinxiang Medical University, No. 88 Jiankang Road, Weihui, Xinxiang 453100, Henan Province, China. jingsong05010403@163.com
Received: June 5, 2024
Revised: August 7, 2024
Accepted: August 12, 2024
Published online: October 15, 2024
Processing time: 112 Days and 22.8 Hours
Core Tip

Core Tip: This study compared the efficacy of single-agent sorafenib targeted therapy and its combination with small particle drug-eluting beads-transarterial chemoembolization (DEB-TACE) in patients with unresectable liver cancer. The results demonstrate that combining small particle DEB-TACE with sorafenib significantly enhances both short- and long-term treatment outcomes compared to single-agent therapy. This combination approach improves liver function, reduces tumor marker levels, boosts overall treatment efficacy, and enhances patient prognosis. This approach is safe, reliable, and holds significant clinical utility.